Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: AcelRX Pharmaceuticals shares sink after public offering announcement

The biotech is offering more than 7 million shares, expecting to raise as much as US$20mln
Small-Cap Snapshot: AcelRX Pharmaceuticals shares sink after public offering announcement
Shares of its common stock have been priced at US$2.75 per share

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is a top decliner after announcing pricing of a public offering of common stock. The biotech is offering more than 7 million shares at a price of US$2.75 per share. The offering is expected to raise US$20mln to be used for general corporate purposes, including the funding of early commercialization efforts. The specialty pharma company develops under-the-tongue therapies for acute pain. Shares of the California-based company were down nearly 13% to US$2.97 in Thursday morning trading.

Zogenix Inc (NASDAQ:ZGNX) shares jumped following positive results from its late-stage trial of its epilepsy drug. The Phase 3 trial showed that its drug ZX008 was able to reduce the frequency of convulsive seizures. The drug is designed to treat children and young adults with Dravet syndrome. Shares of the California-based biotech were up more than 15% to US$53.42.

READ: Zogenix shares pop on impressive Phase 3 results for epilepsy drug

Engility Holdings Inc (NYSE:EGL) shares are up after reports that the government contractor is exploring a sale. The US defense contractor is said to have attracted companies like CACI International Inc and Science Applications International Corp, according to a Reuters report. The company provides engineering and logistics services to US military and civilian agencies. Shares of the company jumped more than 13% to US$35.79.

The Cato Corporation (NYSE:CATO) is another top decliner following disappointing sales in June. The apparel company reported below-expectation same-store sales. Sales decreased by 2% to US$72.9mln compared with sales of US$74.7mln last June. The company operates 1,350 stores in 33 states, 24 fewer stores than last year. Shares of the North Carolina-based company were down more than 13% to US$21.56.

The Russell 2000 Small-Cap Index saw minimal gains in Thursday morning trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full ACRX profile View Profile

AcelRx Pharmaceuticals Timeline

Related Articles

Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
bacteria
June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use